IVVD - Invivyd, Inc.
About Invivyd, Inc. (https://adagiotx.com)
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Robert D. Allen | Chief Scientific Officer | 1970 | $828,180 USD |
| Jill Andersen | Chief Legal Officer & Corporate Secretary | 1973 | $775,710 USD |
| William E. Duke Jr. | Chief Financial Officer, Principal Accounting Officer & Principal Executive Officer | 1972 | $752,777 USD |
| Timothy Lee | Chief Commercial Officer | 1974 | $706,866 USD |
| Julie Green | Chief Human Resources Officer | 1976 | $542,353 USD |
| Katie Falzone | Senior Vice President of Finance | – | – |
| Kristie Coneys Kuhl | Chief Communications Officer | – | – |
| Mark A. Wingertzahn | Senior Vice President of Clinical Development & Medical Affairs | 1971 | – |
| Michael J. Mina | Chief Medical Officer | 1985 | – |
| Rachael Gerlach | Senior Vice President of Regulatory Affairs | – | – |
| Scott Young | Senior Vice President of Investor Relations & Corporate Communications | – | – |